# PregLem

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/preglem

- Industry: Pharmaceuticals
- Headquarters: Geneva, Switzerland
- Website: www.preglem.com
- Total disclosed funding: $69M
- Latest round: Series B (Oct 5, 2010)
- Investors on record: 4

## About

PregLem SA is a Swiss biopharmaceutical company focused on developing innovative treatments for women's health issues, specifically in reproductive health and fertility management.PregLem SA, founded in 2006, is headquartered in Geneva, Switzerland. The company specializes in biopharmaceutical solutions for women's health. In October 2010, PregLem was acquired by Gedeon Richter Plc for CHF 150 million, with potential milestone payments of up to CHF 295 million. The company has completed five significant deals since its inception, establishing a strong presence in the reproductive health market.PregLem SA offers a range of innovative biopharmaceutical solutions tailored to the needs of healthcare providers and patients in the women's health sector. Their products aim to enhance reproductive health management, with particular focus on therapies that support fertility and related conditions. The company caters to a global client base, including healthcare professionals and institutions, across North America, Europe, and Asia.PregLem SA's revenue model centers around B2B transactions and direct-to-consumer sales, primarily through subscription-based services. Clients benefit from ongoing access to their biopharmaceutical products, ensuring they remain updated with the latest treatment options. The company also engages in bulk sales to wholesalers, allowing for wider market reach. Their pricing plans are designed to meet the diverse needs of different customer segments, reflecting the value of their specialized offerings.PregLem SA aims to expand its product portfolio with new treatments in women's health, targeting release by 2011. The recent acquisition by Gedeon Richter Plc will support these initiatives, with the initial cash consideration of CHF 150 million and milestone payments facilitating further research and development. The company plans to explore new markets, particularly in Asia, to broaden its reach and impact in the women's health sector.

## Funding rounds

- Series B, Oct 5, 2010, $10M — MVM Partners, Sofinnova Partners, Sofinnova Investments, NeoMed
- Series B, Dec 14, 2007, $32M — MVM Partners, Sofinnova Partners, Sofinnova Investments, NeoMed
- Series A, Jun 27, 2007, $26M — MVM Partners, Sofinnova Partners, NeoMed
- Seed, Sep 1, 2006, $0.3M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A, Series B
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series A, Series B
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B